| abstract |
The present disclosure is a pharmaceutical composition comprising one or more selective estrogen receptor modulator (s) (SERM (s), such as Lasofoxifene) and four or more pharmaceutically acceptable excipients. Provide the goods. The pharmaceutical composition can form nanodroplets (eg, by self-nanoemulsifying) in vaginal fluid and deliver one or more SERM (s) to the vagina of a female subject obtain. The pharmaceutical composition may be useful for treating or preventing vulvovaginal atrophy, dyspareunia, sexual dysfunction, osteoporosis, or breast cancer in a female subject. |